Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study

February 8th 2015

Kamlesh Khuntiet al. Diabetes Care. Doi: 10.2337/dc14-0920

This study also used CPRD to assess the risks of insulin treatment, this time focusing on the adverse outcome of hypoglycaemia. Hypoglycaemia is a hot topic in diabetes. Compared to older diabetes treatments (sulphonylureas and human insulins) recently launched antidiabetes therapies have a lower hypoglycaemia risk. Severe hypoglycaemia, requiring third-party intervention, is clearly important, however, it is relatively uncommon, especially in clinical trials. Quantifying the importance of mild hypoglycaemia is much more difficult, with agencies such as NICE attributing no financial cost to these episodes. This makes the case for using newer therapies tricky since they are inevitably more expensive. The authors report an increased hazard ratio for cardiovascular disease (CV) and all-cause mortality in subjects who experienced hypoglycaemia, both in type 1 and type 2 diabetes. This would imply a financial burden and this could contribute the economic justification for newer therapies. Once again, however, cause-and-effect cannot be proven; it could be that patients prone to hypoglycaemia are prone to CV events. This type of study can only be hypothesis-generating and prospective studies are needed.
http://care.diabetesjournals.org/content/early/2014/12/02/dc14-0920.abstract

Categories: Journal Watch

Journal Watch Archive

calendar-iconJournal Watch Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Sanofi DiabetesNovo NordiskNapp DiabetesAstraZeneca

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAmgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership